← Leaderboards
Caroline McPhee Leeth
Jackson Laboratory
$893,180
Attributed
$893,180
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $236.8K · FY2014–18$250K$187.5K$125K$62.5K$0
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$893,180 · 2
By mechanism
K08$651,680 · 1
R03$241,500 · 1
Top collaborators
No co-investigators on record.
Most similar at Jackson Laboratory
Same institution · by research overlap
- David V. Serreze$20,047,270
- Tatyana V. Golovkina$20,197,921
- Anna Karolina Palucka$28,504,784
- Christine R Beck$3,453,152
- Peter Gerard Fuerst$1,620,598
Others in their field
Top investigators on “Immunoglobulins”
- Dennis R. Burton · Scripps Research Institute$274,309,511
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$95,592,456
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- James E Crowe · Vanderbilt University Medical Center$56,254,983
- Jeffrey Victor Ravetch · Rockefeller University$39,074,258
Research focus
ImmunoglobulinsLifeB-LymphocytesImmunoglobulin Class SwitchingImmunoglobulin Switch RecombinationLaboratoriesAntibodiesBaseDisease ProgressionHomologous RecombinationImmunoglobulin Somatic HypermutationApoptoticInvestigationAttenuatedAttenuationAutoantibodiesActivated B-LymphocyteAutoimmune DiseasesCellsCessation Of LifeDna Double Strand BreakFutureActivation-Induced Cytidine DeaminaseMediating
Grant awards (8)
Optimizing B-lymphocyte Therapeutic Targeting Strategies in Autoimmune Diabetes$156,297
K08 · FY2018 · DK · contact PI
Optimizing B-lymphocyte Therapeutic Targeting Strategies in Autoimmune Diabetes$156,297
K08 · FY2017 · DK · contact PI
Investigating Immunoglobulin CSR as a Novel Therapeutic Target for SLE$80,500
R03 · FY2017 · AR · contact PI
Optimizing B-lymphocyte Therapeutic Targeting Strategies in Autoimmune Diabetes$148,512
K08 · FY2016 · DK · contact PI
Investigating Immunoglobulin CSR as a Novel Therapeutic Target for SLE$80,500
R03 · FY2016 · AR · contact PI
Optimizing B-lymphocyte Therapeutic Targeting Strategies in Autoimmune Diabetes$148,512
K08 · FY2015 · DK · contact PI
Investigating Immunoglobulin CSR as a Novel Therapeutic Target for SLE$80,500
R03 · FY2015 · AR · contact PI
Optimizing B-lymphocyte Therapeutic Targeting Strategies in Autoimmune Diabetes$42,062
K08 · FY2014 · DK · contact PI